Because no large head-to-head trial had previously compared every licensed dose of the two drugs across a full panel of outcomes, the researchers turned to an established statistical technique known as the Bucher indirect treatment comparison. The method anchors two randomized controlled trials that share a common comparator, in this case placebo, and mathematically derives the relative effect of the two active treatments. The team drew on SURMOUNT-1, the 72-week trial that tested tirzepatide at 5, 10 and 15 milligrams per week, and STEP 1, the 68-week trial that tested semaglutide at 2.4 milligrams per week. Both trials enrolled adults with obesity, defined as a body mass index of 30 or higher, or overweight with at least one weight-related complication such as hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, and both excluded people with type 2 diabetes.

The statistical machinery behind the comparison was more elaborate than a simple subtraction. Before running any numbers, the researchers assessed whether the two trials were similar enough to be compared at all, examining trial design, baseline patient characteristics, placebo responses and outcome definitions. They identified sex and ethnicity as potential treatment effect modifiers, since SURMOUNT-1 enrolled 67.5 percent women and 47.8 percent Hispanic participants while STEP 1 enrolled 74.1 percent women and only 12.0 percent Hispanic participants. To test whether these imbalances distorted the results, they repeated the analysis using matching-adjusted indirect comparisons, a technique that reweights individual patient data from one trial so that its population matches the aggregate characteristics of the other. Reassuringly, the adjusted and unadjusted analyses told broadly the same story.

The headline finding concerns weight itself. Tirzepatide at 10 and 15 milligrams produced statistically significantly greater weight reductions than semaglutide 2.4 milligrams, with mean differences of 5.10 and 6.50 kilograms respectively in favor of tirzepatide. Body mass index fell correspondingly further, by 1.87 and 2.37 kilograms per square meter. Patients on the higher tirzepatide doses were also significantly more likely to cross clinically meaningful thresholds, achieving weight losses of at least 10, 15 and 20 percent of their starting body weight more often than those on semaglutide. The lowest tirzepatide dose, 5 milligrams, showed only non-significant trends in the same direction, effectively performing at a level similar to semaglutide. These numbers align closely with the raw trial results, where tirzepatide 10 and 15 milligrams produced losses of 22.2 and 23.6 kilograms against semaglutide’s 17.4 kilograms.

What sets this analysis apart from earlier comparisons is its reach beyond the bathroom scale. Tirzepatide 10 and 15 milligrams were associated with significantly greater reductions in waist circumference, roughly 5.25 and 5.75 centimeters, a marker of visceral adiposity closely tied to cardiovascular risk. Glycemic control also favored the dual agonist, with small but statistically significant additional reductions in HbA1c and fasting plasma glucose even though all participants had normal glucose metabolism at baseline. Blood pressure told a similar story: every tirzepatide dose produced significantly greater drops in diastolic pressure than semaglutide, ranging from 1.30 to 2.40 millimeters of mercury, while systolic improvements trended in the same direction without reaching significance.

The lipid panel added further nuance. All three tirzepatide doses were associated with significantly greater increases in HDL cholesterol, the so-called good cholesterol, ranging from 3.80 to 5.40 percent relative to semaglutide. The highest dose also produced a significantly greater reduction in triglycerides, and in the adjusted analyses it significantly outperformed semaglutide on total cholesterol as well. Taken together, the authors argue, these improvements across waist circumference, glycemia, HDL, triglycerides and blood pressure suggest tirzepatide could meaningfully shift the constellation of risk factors that define metabolic syndrome, the cluster of abnormalities that precedes type 2 diabetes and cardiovascular disease in millions of people worldwide.

Perhaps the most novel contribution involves body composition, an outcome no previous tirzepatide-versus-semaglutide comparison has examined. In the subgroup of participants who underwent dual-energy X-ray absorptiometry scanning, tirzepatide 15 milligrams was associated with a significantly greater reduction in the percentage of body fat mass, 3.50 percent beyond semaglutide, and a significantly greater increase in the percentage of lean mass, 3.40 percent. All participants on both drugs lost some lean tissue along with fat, an expected consequence of substantial weight loss, but the proportion of the body composed of lean mass shifted more favorably with tirzepatide, likely because absolute fat losses were larger. Visceral fat reductions were similar between the drugs.

Safety, the perennial concern with these gut-hormone mimetics, showed no decisive winner. Gastrointestinal adverse events, nausea and discontinuations due to side effects all trended slightly higher with tirzepatide 10 and 15 milligrams, but none of these differences reached statistical significance. All-cause discontinuation actually favored tirzepatide, with significantly lower odds in several of the adjusted analyses. The authors caution that the placebo arms of the two trials showed different rates of gastrointestinal events, which could subtly bias safety conclusions, and they note that the open-label design of the recent head-to-head SURMOUNT-5 trial may introduce more bias than the double-blind trials used here.

The findings arrive with important caveats. The evidence base rests on just two trials, comparisons were only possible at outcomes both trials reported, and the body composition analyses relied on smaller DEXA subgroups that could not be population-adjusted. The timepoints differed by four weeks, though outcomes had plateaued by then, and STEP 1 included European patients while SURMOUNT-1 did not. The study is also industry-sponsored, with most authors employed by Eli Lilly. Still, the results mirror the direct head-to-head SURMOUNT-5 trial, which found tirzepatide superior on weight and waist circumference, and they extend that picture to individual licensed doses and a far broader set of metabolic outcomes. For clinicians and patients weighing the two injectables, the emerging consensus is becoming hard to ignore: at 10 or 15 milligrams, tirzepatide appears to offer more weight loss, better body composition and broader cardiometabolic benefit than semaglutide 2.4 milligrams, with a safety profile that is, on the evidence so far, essentially equivalent.

Subject of Research: Indirect comparison of tirzepatide versus semaglutide efficacy and safety for obesity treatment in adults without type 2 diabetes

Article Title: Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes

Article References: Ciudin, A., Johansson, E., Zimner-Rapuch, S., Dimitriadis, G. K., Bertrand, M., Curteis, T., Clark, L. J., Fan, L., Sapin, H., & Bergmann, J.-F. (2026). Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02229-6

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02229-6

Keywords: tirzepatide, semaglutide, obesity, weight loss, GLP-1 receptor agonist, GIP, indirect treatment comparison, SURMOUNT-1, STEP 1, cardiometabolic risk factors, body composition, International Journal of Obesity

The work, published in the Journal of Eating Disorders, emerges from the Norwegian Microbiota Study in Anorexia Nervosa, known as NORMA, a project funded by the Norwegian Research Council that examines how gut biology and eating disorders intersect. The team, led by Ida Heir Hovland and Siv Kjølsrud Bøhn of the Norwegian University of Life Sciences together with collaborators at Oslo University Hospital and other Norwegian centers, and including eating disorders researcher Cynthia M. Bulik of the Karolinska Institutet and the University of North Carolina at Chapel Hill, enrolled 42 patients with anorexia nervosa admitted for inpatient treatment and 42 age-matched healthy controls. Blood samples were drawn from patients at baseline, after six weeks, and after twelve weeks of treatment, while the healthy controls provided a single baseline sample for comparison.

The analytical approach was deliberately broad. Using Luminex technology, a bead-based immunoassay platform that can quantify many proteins simultaneously in a small volume of serum, the researchers measured an array of hormones and signaling molecules central to appetite regulation: ghrelin, the stomach-derived hormone that stirs hunger; leptin, the fat-cell hormone that signals long-term energy stores; insulin and C-peptide, markers of pancreatic insulin secretion; adipsin and resistin, adipose-derived factors; adiponectin, another fat-cell hormone with metabolic and anti-inflammatory roles; the incretin hormones GLP-1 and GIP, which are released by the gut after eating and modulate insulin secretion and satiety; glucagon; plasminogen activator inhibitor-1; and visfatin. Dietary intake was captured with a three-day digital food diary and interview, allowing the team to connect hormone levels not just to weight but to what patients actually ate.

The baseline differences were striking. Compared with healthy controls, patients with anorexia nervosa showed significantly lower levels of adipsin, leptin, insulin, and resistin, and significantly higher levels of adiponectin and glucose-dependent insulinotropic polypeptide, or GIP. Ghrelin, the hunger hormone, was also elevated in patients, though the difference fell just short of statistical significance with a p-value of 0.08. No baseline differences emerged for C-peptide, plasminogen activator inhibitor-1, or visfatin. Intriguingly, the size of the group difference in GLP-1 and glucagon depended on age, with discrepancies between patients and controls being greater in older participants, a hint that the hormonal signature of the illness may shift across the lifespan.

These patterns make physiological sense in the context of severe starvation. Leptin is produced by adipose tissue in proportion to fat stores, so its near-absence in emaciated patients is expected. Low insulin reflects reduced nutrient intake and reduced body fat. Elevated ghrelin is the body’s classic cry for food. But the elevated adiponectin and GIP are less intuitive, and their persistence raises questions about whether the gut–brain axis in anorexia nervosa is merely responding to starvation or has been fundamentally rewired by it. Adiponectin typically rises as fat mass falls, yet its other roles in inflammation and energy metabolism suggest it may be doing more than simply tracking body composition.

Then came treatment. Over twelve weeks of structured inpatient care, designed around nutritional rehabilitation, the patients’ mean body mass index rose significantly from 15.5 to 18.2 kilograms per square meter, a substantial gain that nonetheless left most patients below the healthy BMI range. The hormonal response to this refeeding was a study in partial recovery. Adipsin, leptin, insulin, and C-peptide all increased, moving in the direction of healthy control values. Ghrelin decreased and approached the levels seen in controls. In other words, the hormones most tightly coupled to fat mass and acute nutrient flux responded to treatment much as one would predict from basic endocrinology.

But four signals stood apart. Glucagon, adiponectin, GIP, and GLP-1 were largely resistant to change across the twelve weeks of treatment. These are precisely the hormones most entangled with the gut side of the gut–brain axis: GLP-1 and GIP are secreted by intestinal enteroendocrine cells in response to food, and glucagon, produced by the pancreatic alpha cells, governs glucose mobilization during fasting. Their stubbornness suggests that refeeding and weight gain, at least over this timeframe, are not sufficient to normalize every arm of the appetite-signaling network. The authors interpret this as evidence of continued gut–brain axis dysregulation, a molecular echo of the illness that persists even as the body is refed.

Perhaps the most consequential finding of the study concerns diet. When the researchers examined associations between the biomarkers and what patients ate, they found that body mass index alone did not fully account for the hormonal differences between patients and controls. Dietary composition, particularly the intake of fiber and fat, appeared to matter independently for hormone regulation in anorexia nervosa. This is a technically important observation because it implies that the quality and macronutrient profile of the diet, not merely the total energy delivered, may shape how the appetite-signaling system recovers. Fiber is well known to influence gut hormone secretion through fermentation by the gut microbiota, producing short-chain fatty acids that stimulate enteroendocrine L-cells, the very cells that produce GLP-1. Fat intake, meanwhile, influences both incretin release and the absorption kinetics of meals. The NORMA study’s microbiota focus makes this connection especially tantalizing, since the gut bacteria that ferment fiber are themselves altered in anorexia nervosa.

The clinical implications are considerable but deliberately framed as open questions by the authors. Nutritional treatment is a cornerstone of anorexia nervosa care, and weight restoration remains essential, yet the persistence of abnormal levels of glucagon, adiponectin, GIP, and GLP-1 after twelve weeks of intensive treatment suggests that weight gain alone may not fully repair the biological machinery of appetite. Whether these unresponsive hormones can be targeted through tailored nutritional strategies, such as manipulating fiber or fat intake, or through pharmacological therapies aimed at the gut–brain axis, remains to be investigated. The GLP-1 system is already a major drug target in obesity and diabetes, and understanding why it behaves anomalously in anorexia nervosa could open new therapeutic avenues for a disorder where restoring the drive to eat is the central clinical challenge.

The study’s design carries caveats that the authors acknowledge through its framing as exploratory. With 42 patients and 42 controls, the sample is modest, and the healthy controls were only measured once, limiting the ability to model within-person change in that group. Twelve weeks is a short window in the arc of recovery from an illness that often runs a chronic course, and the patients’ BMIs at the end of treatment were still below the healthy range, so it remains possible that some hormones would normalize with further weight restoration. Still, the trial was prospectively registered with ClinicalTrials.gov under identifier NCT06144905, and the longitudinal sampling within treatment gives the findings a temporal texture that cross-sectional studies cannot match. What emerges is a picture of anorexia nervosa as not only a psychological disorder of eating but a systemic endocrine condition, one in which the molecular conversation between gut and brain is disrupted at baseline, partially restored by refeeding, and in key respects strikingly resistant to change. For clinicians and researchers alike, the message is that the scale tells only part of the story, and that the hormones of hunger may hold the rest.

Subject of Research: Appetite-related biomarker changes during inpatient treatment of anorexia nervosa and their association with diet and body mass index

Article Title: Exploring appetite-related biomarkers in anorexia nervosa during treatment: associations with diet and comparison with healthy controls

Article References: Hovland, I. H., Otterdal, K. L., Bang, L., Vinje, H., Herfindal, A. M., Strømland, S. S., Aspholm, T. E., Arsenovic, D., Reistad, H. T., Dahl, J., Ones, M. L., Weider, S., Bulik, C. M., Rø, Ø., & Bøhn, S. K. (2026). Exploring appetite-related biomarkers in anorexia nervosa during treatment: associations with diet and comparison with healthy controls. Journal of Eating Disorders. https://doi.org/10.1186/s40337-026-01752-1

Image Credits: AI Generated

DOI: 10.1186/s40337-026-01752-1

Keywords: anorexia nervosa, appetite hormones, gut-brain axis, ghrelin, leptin, GLP-1, GIP, adiponectin, dietary fiber, nutritional rehabilitation, biomarkers, eating disorders

Incretins occupy a central position in the entero-insular axis, the signalling network by which the gut primes the pancreas to release insulin after a meal in a glucose-dependent manner. GLP-1, a 30-amino-acid polypeptide secreted by L cells of the terminal ileum and colon, binds a G protein-coupled receptor distributed across pancreatic islets, adipose tissue, the cardiovascular system, the central nervous system and, crucially, the reproductive organs. Its classical action involves activation of the cAMP/PKA cascade in pancreatic beta cells, enhancing insulin gene transcription and glucose-dependent insulin secretion. The hormone also regulates voltage-dependent calcium channels to promote calcium influx, suppresses glucagon release from alpha cells, and engages the PI3K pathway to sharpen peripheral insulin sensitivity.

The molecular picture has grown considerably richer in recent years. Researchers identified the adipokine zinc-alpha2-glycoprotein as a possible mediator of the metabolic benefits of GLP-1 receptor agonists, with twelve weeks of liraglutide treatment significantly elevating circulating ZAG levels in patients with type 2 diabetes. Other teams have explored ways to boost the body’s own GLP-1 output: the dietary compound imperatorin and glycyrrhizic acid, a principal component of licorice, both activate the TGR5 receptor to enhance GLP-1 secretion in experimental models. Even receptor architecture is proving malleable—bioluminescence resonance energy transfer studies revealed that the GLP-1 receptor can form heterodimers with the secretin receptor in islet cells, altering calcium signalling and inducing cross-desensitisation between the two receptors.

GIP, the second major incretin, is a 42-amino-acid peptide produced by K cells in the duodenum and jejunum. Though less intensively studied than GLP-1, it promotes insulin biosynthesis, supports beta-cell differentiation and survival, and enhances fat storage and bone formation. Work by Samms and colleagues showed that GIP enhances lipoprotein lipase activity in adipocytes through a PI3K/PKB-LKB1/AMPK-TORC2 signalling axis, promoting lipid uptake and storage while increasing insulin sensitivity. Intriguingly, GIP and GLP-1 signalling appear intertwined: N-glycosylation-deficient GIP receptors can be functionally rescued by co-expression with wild-type GLP-1 receptors, hinting at functional heterodimerisation between the two receptor classes.

The most clinically mature application in gynaecology is polycystic ovary syndrome, a condition characterised by hyperandrogenemia and insulin resistance that affects a growing number of women worldwide. Studies have confirmed abnormal secretion of both GIP and GLP-1 in patients with PCOS, and clinical research has shown that GLP-1 receptor agonists such as liraglutide and semaglutide can improve menstrual regularity, raise ovulation rates and reduce body fat. Mechanistically, the agonist exenatide was found to improve insulin resistance in PCOS rats by activating the AMPKalpha-SIRT1 pathway, while GLP-1 receptor agonists more broadly bolster antioxidant defences via the Nrf2/ARE pathway and reduce endoplasmic reticulum stress through modulation of the PERK pathway.

Genetic evidence adds weight to the GIP connection. A two-sample Mendelian randomisation analysis found that genetic activation of the GIP receptor is associated with a reduced risk of PCOS, and animal work shows that GIP signalling regulates the oestrous cycle and female fertility through the pituitary-gonadal axis. The gut microbiome may also be a critical link: dysbiosis in PCOS elevates the microbial metabolite agmatine, which activates the farnesoid X receptor and suppresses GLP-1 secretion from intestinal L cells, contributing to insulin resistance and ovarian dysfunction. This agmatine-FXR-GLP-1 axis offers a compelling explanation for how gut health, metabolism and reproduction converge in the syndrome.

Beyond the ovary, incretins display striking anti-inflammatory and anti-fibrotic properties with direct relevance to uterine disease. GLP-1 suppresses macrophage inflammatory factors including IL-1beta, IL-6 and TNF-alpha, and gene therapy studies in obese diabetic mice showed reduced macrophage infiltration of adipose tissue and inhibition of NF-kappaB and JNK signalling. In models of intrauterine adhesion, semaglutide alleviated fibrosis and inflammation by modulating NF-kappaB and reducing fibrotic markers such as ACTA2, COL1A1 and FN, while dulaglutide improved endometrial thickness and reduced collagen deposition by suppressing M1 macrophage polarisation and the TGF-beta/Smad2 pathway. Preclinical studies likewise suggest GLP-1 receptor agonists can inhibit the proliferation of ectopic endometrial cells in endometriosis through PI3K/Akt and NF-kappaB pathways.

The anti-tumour signals are tantalising but preliminary. In endometrial cancer cell lines, liraglutide inhibited proliferation in a time- and concentration-dependent manner, activating AMPK, upregulating progesterone receptors and synergising with medroxyprogesterone acetate. Autophagy appears central: liraglutide induced autophagic cell death by increasing LC3 expression and p-AMPKalpha while decreasing SQSTM1. For ovarian cancer, GLP-1 receptor expression has been documented in some tumour tissues, and agonists can curb proliferation and invasion via AMPK in vitro—but the authors are careful to stress that these anti-tumour effects may be partly secondary to weight loss and improved metabolic status, and direct effects require clinical validation.

Perhaps the most conceptually ambitious frontier is the brain-gut axis. Incretins directly modulate the hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes, and electrophysiological recordings show GLP-1 acting on GnRH neurons to increase firing rates and GABAergic synaptic input. GLP-1 receptor agonists may increase pulsatile GnRH release via the hypothalamic kisspeptin system, influencing luteinising hormone secretion, while peripherally promoting follicular development and oocyte maturation through effects on theca cells. GIP receptor knockout mice exhibit disrupted oestrous cycles and reduced fertility, underscoring GIP’s non-redundant role. Notably, a dual GLP-1/oestrogen agonist improved ovarian cyclicity and insulin sensitivity in PCOS mouse models without direct estrogenic proliferative effects on the uterus.

Clinical translation, however, demands caution. Combination therapy with metformin outperforms metformin alone for weight, BMI and insulin sensitivity, and semaglutide reduced lingual fat in women with PCOS in a randomised trial—yet adverse events are more frequent with combination regimens, and real-world data show 17.8% of patients are non-responders to semaglutide or liraglutide for obesity. Gastrointestinal symptoms remain the most common side effects, and safety concerns persist regarding gallbladder disorders, pancreatitis and rodent C-cell findings. Use in pregnancy and lactation is not recommended, with regulators advising contraception and a two-month washout before conception. For endometriosis, intrauterine adhesions and gynaecological cancers, the evidence remains almost entirely preclinical. The authors call for large, multicentre randomised trials with reproductive outcomes as primary endpoints, dedicated exploration of dual GIP/GLP-1 agonists such as tirzepatide, and tissue-specific studies to disentangle direct hormonal actions from the indirect fruits of metabolic improvement. Incretin-based therapy, they conclude, represents a promising interdisciplinary bridge between endocrinology and gynaecology—one whose full span has yet to be built.

Subject of Research: The role and mechanisms of the incretin hormones GLP-1 and GIP in gynaecological diseases

Article Title: The Role and Mechanism of Incretins in Gynaecologic Diseases

Article References: Yan, J., Cao, M., Ding, Y., Zhang, Y., Sun, Y., Jiang, G., Zhang, Y., Kang, L., Zhou, X., Luo, J., & Li, B. (2026). The Role and Mechanism of Incretins in Gynaecologic Diseases. Endocrinology, Diabetes & Metabolism, 9(5), Article e70340. https://doi.org/10.1002/edm2.70340

Image Credits: AI Generated

DOI: 10.1002/edm2.70340

Keywords: incretins, GLP-1, GIP, polycystic ovary syndrome, endometrial cancer, endometriosis, intrauterine adhesions, insulin resistance, brain-gut axis, GLP-1 receptor agonists, semaglutide, women's health

The stakes of this comparison are enormous. Type 2 diabetes now affects an estimated 589 million adults worldwide as of 2024, a figure projected to climb to 853 million by 2050. Because the disease drives complications through both chronic hyperglycemia and the twin burdens of obesity and cardiovascular disease, contemporary treatment guidelines no longer ask simply whether a drug lowers glucose. They demand sustained reductions in hemoglobin A1c, meaningful weight reduction, cardiovascular safety, and tolerability that patients can live with for decades. Both tirzepatide and dulaglutide are once-weekly subcutaneous injections, but they work differently at the molecular level, and until now no trial had ever compared all clinically relevant doses of the two drugs simultaneously.

Dulaglutide is a selective glucagon-like peptide-1 receptor agonist, a class of drugs that mimics an intestinal hormone to boost glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. It carries hard cardiovascular outcome evidence: in the landmark REWIND trial, dulaglutide reduced major adverse cardiovascular events compared with placebo in people with type 2 diabetes. Tirzepatide, by contrast, is a first-in-class dual agonist that engages both the GIP and GLP-1 receptors, amplifying the incretin effect through two complementary hormonal pathways. Head-to-head trials had already hinted that tirzepatide’s dual mechanism translated into greater reductions in HbA1c and body weight, but individual studies compared only selected dose pairs, leaving clinicians without a comprehensive map of which specific dose delivers which specific benefit.

The research team, following Cochrane Handbook methodology and PRISMA reporting guidelines with a prospectively registered protocol, searched four major databases through the end of 2025 and identified four eligible randomized trials. Three of these were judged to carry low risk of bias across all assessed domains; the fourth, an open-label switching study, raised some concerns because participants and clinicians knew which treatment was being given. The largest trial by far was the SURPASS-CVOT cardiovascular outcomes study, which enrolled 13,165 patients with established atherosclerotic cardiovascular disease and demonstrated that tirzepatide titrated up to 15 milligrams was noninferior to dulaglutide 1.5 milligrams for the composite of cardiovascular death, myocardial infarction, or stroke over a median follow-up of roughly four years.

Using a frequentist random-effects network model, the analysts computed treatment effects and SUCRA rankings, a statistical measure of each dose’s cumulative probability of being among the most effective options. The results formed a clean dose-response gradient. For glycemic control, tirzepatide 15 milligrams ranked highest at both 12 and 24 weeks, achieving SUCRA values of 0.95 and 0.99 respectively, while dulaglutide 1.5 milligrams sat near the bottom of the efficacy rankings. At 24 weeks, tirzepatide 15 milligrams reduced HbA1c significantly more than tirzepatide 5 milligrams, and both dulaglutide 0.75 and 1.5 milligrams were associated with meaningfully smaller reductions. The differences of 0.2 to 0.4 percentage points between higher and lower tirzepatide doses are clinically meaningful, because shifts of that magnitude can move patients across standard treatment targets and delay the need for therapy intensification.

The weight findings followed the same pattern with even sharper separation. By week 16, tirzepatide 15 milligrams outperformed tirzepatide 5 milligrams by an additional 2.68 kilograms of weight loss, and the contrast against the weakest doses was dramatic: dulaglutide 0.75 milligrams and tirzepatide 1 milligram trailed the top dose by roughly 5 to 8 kilograms. Tirzepatide 15 milligrams earned a SUCRA of 0.95 for weight reduction, with the 10 milligram dose close behind, while tirzepatide 1 milligram ranked nearly last. Notably, the early weight outcomes showed substantial statistical heterogeneity, which the authors attribute to the sensitivity of short-term weight trajectories to titration schedules, baseline body mass index, diabetes duration, and transient gastrointestinal symptoms that can temporarily suppress food intake during dose escalation.

Safety told the mirror-image story. Tirzepatide 1 milligram carried the lowest risk of any treatment-emergent adverse event and of nausea, while dulaglutide 0.75 milligrams showed the lowest risks of diarrhea and vomiting. At the other end of the spectrum, both tirzepatide 15 milligrams and dulaglutide 1.5 milligrams were associated with significantly higher nausea risk compared with tirzepatide 5 milligrams. This gradient is biologically coherent: higher incretin receptor engagement intensifies slowed gastric emptying and central satiety signaling, which are precisely the mechanisms that drive both the metabolic benefits and the gastrointestinal complaints. Encouragingly, no significant differences emerged between any dose pairs for all-cause death, severe hypoglycemia, serious adverse events, pancreatitis, treatment discontinuation, or the composite cardiovascular endpoint, although the authors caution that wide confidence intervals for these rare outcomes mean the absence of statistical differences cannot be read as proof of equivalent safety.

The team stress-tested their findings with a battery of sensitivity analyses, including one that removed the dominant SURPASS-CVOT trial entirely to check whether its enormous statistical weight was distorting the network. The core conclusions held. Some outcomes, notably HbA1c at 12 weeks, early body weight change, and nausea and vomiting, proved sensitive to the inclusion of the Japanese SURPASS J-mono trial, which compared tirzepatide against the 0.75 milligram dulaglutide dose approved in Japan rather than the 1.5 milligram standard used elsewhere. Inconsistency testing using both design-by-treatment interaction models and node-splitting found no meaningful disagreement between direct and indirect evidence for most outcomes, lending credibility to the network’s internal structure.

The clinical implications are refreshingly practical. For patients whose primary goals are maximal HbA1c reduction and weight loss, the data support escalating to tirzepatide 10 or 15 milligrams when tolerability permits, with an expected stepwise advantage over lower doses and over any dulaglutide regimen. For patients whose priority is gastrointestinal tolerability, starting at lower doses such as dulaglutide 0.75 milligrams or tirzepatide 1 milligram remains a reasonable strategy, accepting more modest metabolic gains and possible later intensification. The findings also reinforce the results of the SURPASS-SWITCH trial, which showed that patients inadequately controlled on submaximal dulaglutide achieved greater HbA1c and weight improvements by switching to tirzepatide than by pushing the dulaglutide dose higher. An important interpretive caveat applies to the early time points: many participants assigned to the highest tirzepatide doses were still in protocol-mandated dose escalation at weeks 12 and 16, meaning the full maintenance-dose effects may be even larger than these figures suggest.

The authors are candid about the limitations. Only four trials informed the network, several dose nodes rested on sparse comparisons, and long-term durability, late adverse events, and sustained discontinuation could not be assessed because later time points were not consistently reported across trials. Some data were digitized from published figures, introducing the possibility of minor extraction error despite independent double-checking. Still, within those constraints, the analysis delivers something no single trial could: a unified, dose-level ranking of the two most widely used once-weekly injectable therapies for type 2 diabetes. The message for the millions of patients and their clinicians navigating this decision is one of individualized titration, balancing the escalating metabolic rewards of higher tirzepatide doses against the dose-related gastrointestinal costs, with the reassurance that cardiovascular safety appears preserved across the spectrum.

Subject of Research: Comparative efficacy and safety of tirzepatide versus dulaglutide doses in type 2 diabetes

Article Title: Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta‐Analysis of Randomized Clinical Trials

Article References: Hageen, A. W., Gadelmawla, A. F., Saleh, A. O., Bahnasy, S., Eladawi, S., Abdelaziz, M., Iyad, K., Kandil, A. H., Zinhom, K., Mohamed, M. R., Abdulhay, H., Turkman, M., Abdelazeem, B., & Fonarow, G. C. (2026). Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta‐Analysis of Randomized Clinical Trials. Endocrinology, Diabetes & Metabolism, 9(5), Article e70313. https://doi.org/10.1002/edm2.70313

Image Credits: AI Generated

DOI: 10.1002/edm2.70313

Keywords: tirzepatide, dulaglutide, type 2 diabetes, network meta-analysis, HbA1c, weight loss, GLP-1 receptor agonist, GIP, cardiovascular outcomes, gastrointestinal adverse events, dose-response, incretin therapy

The rationale for the experiment rests on how differently the two drug classes act. Incretin-based therapies such as semaglutide and tirzepatide mimic gut-derived hormones that slow gastric emptying, enhance insulin secretion and signal to brainstem and hypothalamic circuits that suppress appetite. Amylin-based agents such as cagrilintide act on a distinct receptor complex, the amylin receptor formed by AM-LNR in combination with the calcitonin receptor CALCR, and appear to reduce food intake through partly separable neural pathways. Retatrutide, the most advanced triple agonist in clinical development, adds glucagon receptor activity, which in preclinical models is associated with increased energy expenditure and favorable effects on lipid metabolism. The Copenhagen group reasoned that engaging all five receptors at once might capture complementary benefits that no single molecule, however sophisticated, could deliver.

To test this, the researchers used diet-induced obese male rats, a standard preclinical model in which animals become obese after prolonged exposure to a high-fat diet. Animals received daily subcutaneous injections of cagrilintide, retatrutide, the two drugs co-administered, or comparator regimens built around semaglutide and tirzepatide at matched doses. The results were striking: co-administration of cagrilintide and retatrutide produced dose-dependent reductions in body weight and food intake that surpassed both equimolar monotherapies and matched-dose combinations incorporating the established incretin drugs. Across multiple studies, the combination also reduced fat-pad masses and improved circulating markers of metabolic health, including total cholesterol, triglycerides and insulin, without evidence of the liver enzyme elevations that can signal hepatic stress.

A central question in obesity pharmacology is whether a drug simply makes animals eat less or whether it does something more. The team addressed this with pair-feeding and weight-matching experiments, designs in which control animals are given either the same amount of food as treated animals or are calorie-restricted until their body weight matches that of drug-treated animals. These experiments revealed that the enhanced weight loss seen with the combination could not be explained by reduced food intake alone. In other words, even when caloric intake was held constant, the cagrilintide-retatrutide pairing drove greater reductions in body weight than calorie restriction by itself, pointing to additional mechanisms, potentially involving energy expenditure, nutrient partitioning or the glucagon receptor’s effects on lipid handling.

The study went beyond physiology into molecular territory. Using advanced mass spectrometry workflows, including enrichment of extracellular vesicles from plasma, the researchers profiled the circulating proteome of treated animals. Plasma proteomic analysis showed that the combination therapy was associated with enrichment of proteins involved in bioenergetic processes, a signature consistent with altered fuel metabolism rather than mere caloric deprivation. By comparing drug-treated animals with weight-matched calorie-restricted controls, the team could separate molecular changes that simply track weight loss from those that are drug-specific, an analytical distinction they argue is essential for interpreting the biology of next-generation anti-obesity therapies.

The brain was the other major focus. Obesity drugs act centrally, and the specific neuronal programs they engage determine both their efficacy and their side-effect profile. The researchers performed bulk RNA sequencing of two key brain regions: the hypothalamus, the master hub of energy homeostasis, and the dorsal vagal complex in the brainstem, a critical relay for visceral sensory information and a major site of action for GLP-1-based drugs. Brain transcriptomic profiling revealed convergent central neuronal programs linked to energy balance regulation, and importantly, the combination therapy elicited stronger responses in hypothalamic and dorsal vagal complex gene modules than either monotherapy. The team used co-expression network analysis and cell-type enrichment mapping to connect these transcriptional signatures to specific neuronal populations, and found that modules activated by the combination were enriched for genes previously associated with human body mass index in genome-wide association studies.

These molecular findings carry practical implications for drug design. The field is currently racing to develop unimolecular multi-receptor agonists, single peptides engineered to bind several receptors at once, exemplified by retatrutide itself and by amycretin, a GLP-1 and amylin receptor co-agonist that has shown promising results in early clinical trials. The Copenhagen study suggests a blueprint for such molecules: a next-generation single agent that combines GLP-1, GIP, glucagon and amylin receptor activity in one backbone could, in principle, reproduce the pharmacology of the cagrilintide-retatrutide pair without requiring two separate injections. The authors frame their preclinical data as direct guidance for the design of these next-generation unimolecular agonists, identifying which receptor combinations and dose ratios appear most productive.

The clinical context makes the findings timely. Retatrutide has delivered powerful weight loss in a pivotal phase 3 obesity trial, and co-administered cagrilintide and semaglutide, marketed as a fixed-dose combination, has already demonstrated substantial efficacy in adults with overweight or obesity. Yet a persistent challenge remains in achieving maximal weight loss and metabolic control, particularly for patients living with both obesity and type 2 diabetes. The Copenhagen study suggests that adding amylin receptor agonism on top of a triple incretin agonist may push efficacy further than simply optimizing incretin pharmacology alone. The researchers also probed tolerability signals, including conditioned taste aversion tests in lean rats, which are used as a proxy for nausea-like aversive effects, and found dose-dependent responses that will inform how such combinations might be titrated in future studies.

Important caveats apply. All of the efficacy data come from male rats, and sex differences in response to obesity pharmacotherapy are well documented, so replication in female animals and eventually in humans will be essential. The doses used in rodents also cannot be translated directly to the clinic, and combination therapy raises questions about tolerability, cost and dosing complexity that only human trials can resolve. Nonetheless, the study provides one of the most comprehensive preclinical characterizations to date of what happens when the incretin and amylin systems are engaged simultaneously, integrating behavioral, metabolic, proteomic and transcriptomic readouts within a single experimental framework. The underlying data, including proteomic datasets deposited in the PRIDE repository and gene expression data in ArrayExpress, along with all analysis code released on GitHub, have been made openly available to the research community.

As obesity medicines evolve from single-hormone mimics toward rationally designed polypharmacology, the Copenhagen results make a compelling case that the amylin system is the most promising partner for the incretin drugs that have already transformed the field. If the five-receptor strategy translates from rats to humans, the ceiling on pharmacologically achievable weight loss, long constrained by the limits of GLP-1 receptor agonism, may be considerably higher than anyone dared to project just a few years ago.

Subject of Research: Combination therapy with cagrilintide and retatrutide for enhanced weight loss and metabolic outcomes in obese rats

Article Title: Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats

Article References: Petersen, J., Merrild, C., Holm, S. K., Kurgan, N., Hassan, S., Mathiesen, C. V., Börchers, S., Svendsen, C., D’Anna, S., Andersen, N. R., Klein, A. B., Fritzen, A. M., Deshmukh, A. S., Pers, T. H., & Clemmensen, C. (2026). Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. Nature Metabolism. https://doi.org/10.1038/s42255-026-01603-y

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01603-y

Keywords: cagrilintide, retatrutide, obesity, GLP-1 receptor agonist, amylin, glucagon receptor, GIP, weight loss pharmacotherapy, Nature Metabolism, multi-receptor agonist, metabolic health, preclinical study